Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ABC-X
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- NCT03340129 ↗
- Recruiting
- Melanoma Institute Australia
- Focused
We haven't built an HCP commentary report on ABC-X (nivolumab plus ipilimumab plus stereotactic radiotherapy in melanoma brain metastases) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ABC-X so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Melanoma Stage Iv
- Interventions
- Ipilimumab; Nivolumab; Stereotactic Radiotherapy; Salvage therapy
- Arms
- Nivolumab + ipilimumab · Active comparator
- Nivolumab + ipilimumab,concurrent SRS · Active comparator
- Enrollment
- 218 (estimated)
- Primary outcomes
- Neurological specific cause of death
- Sponsor
- Melanoma Institute Australia with Bristol-Myers Squibb
- Start
- Aug 14, 2019
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03340129 · updated Oct 8, 2026
Publications
linked from the registry- Phillips WJ, Baghai T, Ong M, Lo B, Ibrahim AM, Smith TKT, Song X. A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases. Curr Oncol. 2021 Jan 13;28(1):428-439. doi: 10.3390/curroncol28010045. PubMed 33450821